Dolby Laboratories, INC Form 4 insider transactions

Ryan Nicholson, VP, CAO and Corp. Controller of Dolby Laboratories, Inc., sold 357 shares of common stock on August 4, 2026 for $60.63 per share.

John D Couling, SVP, Entertainment of Dolby Laboratories, Inc., sold 7,667 shares of common stock on August 3, 2026.

Dolby Laboratories SVP John Couling reported transactions involving Class A Common Stock, including the acquisition of shares under an employee stock option and the sale of shares.

John D. Couling, SVP of Entertainment at Dolby Laboratories, Inc., reported transactions involving Class A Common Stock, including acquisitions and dispositions, executed under a Rule 10b5-1 trading plan.

Dolby Laboratories SVP and Chief Marketing Officer Todd Pendleton sold 11,876 shares of Class A common stock on May 22, 2026.

SVP of Advanced Technology Group Shriram Revankar sold 3,000 shares of Dolby Laboratories stock under a 10b5-1 trading plan.

Dolby Laboratories SVP and CFO Robert Park sold 4,895 shares of Class A common stock on May 12, 2026.

Dolby Laboratories SVP John Couling exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Dolby Laboratories Director Emily Rollins reported a transaction involving 1,000 shares of Class A Common Stock on April 1, 2026.

Dolby Laboratories director and 10% owner Dagmar Dolby reported a charitable gift of 10,000 Class A shares and an estate planning transfer of 1 million Class B shares.

Dagmar Dolby, a Director and 10% owner of Dolby Laboratories, converted and gifted 380,000 shares of Class A Common Stock to a charitable organization.

Dolby Laboratories CEO Kevin Yeaman transferred 145,252 employee stock options to a revocable trust for estate planning purposes.

Dolby Laboratories Director Simon Segars received a grant of 3,908 restricted stock units, increasing his beneficial ownership to 47,150 shares.

Dolby Laboratories Director David Dolby was granted 3,908 restricted stock units, increasing his beneficial ownership to 92,718 shares.

Dolby Laboratories Director Emily Rollins was granted 3,908 restricted stock units, increasing her beneficial ownership.

Dolby Laboratories Director Peter Gotcher received an award of 3,908 restricted stock units, aligning his interests with shareholders.

Dolby Laboratories director Anjali Sud received a grant of 3,908 restricted stock units, aligning her interests with shareholders.

Dolby Laboratories Director Tony Prophet received a grant of 3,908 restricted stock units, increasing his beneficial ownership to 13,015 shares.

Dolby Laboratories Director Avadis Tevanian received an award of 3,908 restricted stock units as part of his compensation.

Dolby Laboratories' SVP of Entertainment, John D. Couling, reported a planned future sale of 6,667 Class A Common Stock shares at $64.885 per share under a Rule 10b5-1 plan.

Dolby Laboratories' SVP of Entertainment, John D. Couling, reported new grants of restricted stock units, performance-based units, and stock options, alongside shares withheld for tax obligations.

Dolby Laboratories VP, CAO, and Corporate Controller Ryan Nicholson reported the grant of 9,032 restricted stock units and subsequent tax-related dispositions of shares.

Dolby Laboratories' SVP and Chief Marketing Officer, Todd Pendleton, reported the acquisition of new restricted stock units and stock options, alongside the vesting of performance-based units and tax-related share disposals.

Dolby Laboratories CEO Kevin Yeaman reported a series of equity transactions, including new stock and option grants, vesting of previous awards, and sales of shares under a 10b5-1 trading plan.

Dolby Laboratories' SVP of Advanced Technology Group, Shriram Revankar, reported significant equity grants and option awards, alongside tax-related share dispositions.

Dolby Laboratories' EVP, General Counsel & Secretary, Mark Andrew Sherman, reported multiple equity transactions including RSU grants, PSU vesting, option grants, and stock sales.

Dolby Laboratories' SVP & CFO Robert Park reported new grants of restricted stock units, performance-based restricted stock units, and employee stock options, alongside shares withheld for tax obligations.

Dolby Laboratories' SVP of Entertainment, John D. Couling, sold 7,273 shares of Class A Common Stock for $68.75 per share under a pre-arranged 10b5-1 trading plan.

Dolby Laboratories President and CEO Kevin J. Yeaman reported exercising stock options and selling Class A Common Stock on December 9, 2025, through a Rule 10b5-1 plan.

Dolby Laboratories' EVP, General Counsel & Secretary, Mark Andrew Sherman, exercised stock options and subsequently sold an equal number of Class A Common Stock shares under a pre-arranged 10b5-1 plan.